Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca Sells Small-Molecule Antibiotics To Pfizer But Still Investing In R&D

Executive Summary

AstraZeneca is selling its late-stage small molecule antibiotics business to Pfizer in a deal that could reach more than $1.5bn, but the company – one of just a few big pharmas working in antibiotics R&D – says it will continue to study novel antibiotics via its MedImmune biologics division.


Related Content

Alarm As Novartis Exits Antibiotics Space
Pfizer Biosimilars And Anti-Infectives Get Higher Profile Under New Structure
Pfizer Essential Health Is Staying Put And Has A Focused Strategy For Growth
Biopharma Quarterly Dealmaking Statistics, Q3 2016
AstraZeneca’s Business Development Head Grady Outlines Strategy Mix
AZ's Zavicefta Gains EU Positive Opinion For “Superbug” Infections
AstraZeneca Will Establish Antibiotic Subsidiary With $40 Million
Under Pressure: Can Merck Show Cubist Is Worth $9.5 Billion Without Cubicin?
AstraZeneca Straddles The Fence On Antibiotics; Is It About To Fall Off?
Antibiotic Market Snapshot: In Exchange For Higher Prices, More Value


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts